This article is sponsored by Promega.

In today’s fast-paced RNA therapeutic development landscape, experience matters. With over 40 years of experience in RNA synthesis by in vitro transcription (IVT), Promega smooths the transition from research to production by reducing risk and saving time, without compromising the quality of RNA synthesis in an RNA therapeutic manufacturing workflow.

The mRNA therapeutics landscape is evolving rapidly. Once confined to niche research, mRNA technologies have surged to the forefront of drug development, propelled by Covid-19 vaccines, growing recognition of their potential across various diseases and the utilisation of AI to help reduce development timelines. As the industry continues to push the development of new therapies, the challenge of scaling efficiently from discovery to full-scale production while maintaining quality and regulatory compliance remains. For over 40 years, Promega has been a part of the discovery and innovation of RNA-based therapies by supplying high-quality IVT reagents. We understand that a smooth transition from innovation to commercialisation is critical to success.

Consistent quality at every stage

At Promega, commitment to quality is embedded in every step of our manufacturing processes, with ISO certifications (ISO 9001, ISO 13485, and ISO 18385) maintained at the Promega Madison, USA, facility. Our adherence to strict quality system standards includes detailed manufacture and QC documentation, production and process controls, traceable product batch records, product stability programmes, product change control and notification procedures, supplier evaluation and qualification, equipment maintenance and calibration programme, nonconforming product and complaint-handling procedures and design controls.

IVT reagents for RNA production are produced in state-of-the art facilities, whether you need research-grade or GMP-grade, and meet the quality and regulatory requirements appropriate to the stage of your drug development journey while maintaining consistent performance. Our high-quality research grade materials are ideal for early process development, while our animal origin-free GMP-grade reagents are manufactured under more stringent controls with additional impurity testing (endotoxin, bioburden, and host-cell nucleic acid contamination tests) to support clinical and commercial production.

Scalable and flexible manufacturing to meet your needs

Scaling your RNA synthesis workflow doesn’t have to be complicated. As a primary manufacturer of IVT raw materials, we control all aspects of product manufacture, from raw materials through finished product. At Promega, we offer a simple pathway to scale-up, supporting your needs as they evolve.

Consistency in scale-up: Use the same raw materials from R&D to commercialisation but with product quality attributes appropriate for your stage.

Flexible Order Quantities: No significant minimum order quantities, so you can scale at your own pace.

Customisable Formats and Formulations: Tailored to specific workflows to improve efficiency and streamline production.

Reliable Supply Chain: Decades of experience and a global logistics network ensure consistent, timely delivery wherever you operate, reducing supply chain concerns.

These advantages help reduce bottlenecks and allow for a more predictable production process that can be adapted to your evolving needs.

Shorten your path to success with high-quality IVT raw materials

Our animal origin-free, cGMP-manufactured IVT raw materials are tailored to meet the stringent demands of RNA therapeutic production, from initial development to clinical trials and commercial production.

  • T7 RNA Polymerase: Available in standard (80U/µl) and high (400U/µl) concentrations
  • RNasin Plus Ribonuclease Inhibitor: Offered in standard (40U/µl) and high (500U/µl) concentrations
  • Inorganic Pyrophosphatase (2U/µl)
  • Enzyme Mixes: Mixture of T7 RNA Polymerase, RNasin Plus Ribonuclease Inhibitor, and Inorganic Pyrophosphatase in standard or customised formulation
  • Ribonucleotides: rATP, rGTP, rCTP, rUTP (100mM).
  • Recombinant Proteinase K Solution (20mg/ml)

Promega animal origin-free IVT reagents bring reliability, compliance and scalability to RNA production, supporting every phase of therapeutic development. By partnering with Promega, your organisation can focus on advancing transformative treatments efficiently. Let decades of experience and proven quality systems support your RNA therapeutic development to commercialisation journey.

Learn more.